Claude Bertrand started on Monday in his new role as general director of research and development (R&D) and chief scientific officer (CSO) at privately-held French drugmaker Servier.
Dr Bertrand’s departure from another French pharma company, Ipsen (Euronext: IPN), where he was also CSO, was announced in December 2016.
Ipsen revealed that Dr Bertrand was leaving to join an unnamed company and his destination has now been confirmed by Servier, where he will work with Emmanuel Canet, executive vice president of R&D, before succeeding him as head of the directorate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze